The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...

The FDA has issued a CRL regarding the sBLA for aflibercept 8mg injection for the addition of extended dosing intervals across all approved indications.